Updated on 13 November 2013
Mr Gao further added in the press statement that further scrutiny of foreign businesses in China is going on. "No one has asked foreign companies to be a moral model, but they have to serve as good examples," he explained.
Further, US authorities also have stepped up their scrutiny of multinational companies' activities in China. They have been checking if pharmaceutical companies have violated the Foreign Corrupt Practices Act (FCPA), by paying bribes to government officials in various countries, including China. Under the FCPA, doctors and other employees of government-run hospitals are considered government officials. Glaxo and the other companies say they are cooperating with the US investigation.
GSK on the other hand is said to be investigating allegations from an anonymous tipster that its China-based sales staff was involved in widespread bribery of doctors to prescribe drugs, in some cases for unauthorized uses, between 2004 and 2010. A Glaxo spokesman has said in June that the company is investigating the allegations.
China's official Xinhua News Agency reported that detained executives include Liang Hong, Glaxo's China vice president and operations manager, Zhao Hongyan, a legal-affairs director for the company, Zhang Guowei, a human-resources director and Huang Hong, a business-development manager.